Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Stopped early · Phase 1

Conditions studied: B-cell Non Hodgkin Lymphoma, Richter's Transformation

In brief

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

Key facts

Study ID

NCT03778073

Run by

TG Therapeutics, Inc.

People needed

18

Starts

2019-04-17

Expected to finish

2022-08-01

Last updated by the study team

2022-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• TG Therapeutics Investigational Trial Site — Huntsville, Alabama, United States
• TG Therapeutics Investigational Trial Site — Tucson, Arizona, United States
• TG Therapeutics Investigational Trial Site — Fayetteville, Arkansas, United States
• TG Therapeutics Investigational Trial Site — Peoria, Illinois, United States
• TG Therapeutics Investigational Trial Site — Fort Wayne, Indiana, United States
• TG Therapeutics Investigational Trial Site — Fairway, Kansas, United States
• TG Therapeutics Investigational Trial Site — Louisville, Kentucky, United States
• TG Therapeutics Investigational Trial Site — Charlotte, North Carolina, United States
• TG Therapeutics Investigational Trial Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.